Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.

[1]  P. Gobbi,et al.  Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma , 2020, Hematological oncology.

[2]  L. Cavelier,et al.  Cell‐of‐origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B‐cell lymphoma , 2019, American journal of hematology.

[3]  D. Scott,et al.  COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. , 2019, Blood advances.

[4]  S. Lee,et al.  Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience , 2018, Asian Pacific journal of cancer prevention : APJCP.

[5]  J. Burke,et al.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Rosenwald,et al.  Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Copie-Bergman,et al.  BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Zelenetz,et al.  Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B‐cell lymphoma in the rituximab era , 2015, British journal of haematology.

[9]  L. Staudt,et al.  Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[11]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[12]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[13]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[16]  Andrew Lister,et al.  Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[18]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.